FindTrial
Sign In

Clinical Characterization and Application of Ultra-Deep NGS Sequencing of ctDNA in Breast Cancer Patients for Early Detection and Surgical Treatment Monitoring

Clinical Characterization and Application of Ultra-Deep NGS Sequencing of ctDNA in Breast Cancer Patients for Early Detection and Surgical Treatment Monitoring

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017345
Enrollment
Unknown
Registered
2018-07-25
Start date
2018-07-25
Completion date
Unknown
Last updated
2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Gold Standard:Tumor tissue DNA testing
Index test:Plasma ctDNA testing

Sponsors

Vienomics Ltd. Corp.
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with primary breast cancer (including carcinoma in situ) who are undergoing surgery, regardless of histological type; (2) Women aged 18 or over; (3) Voluntary signing of informed consent; (4) Provide surgical or biopsy pathological tissue samples containing sufficient cancer cells; (5) Follow up and provide peripheral blood in compliance with the time point specified in the clinical trial.

Exclusion criteria

Exclusion criteria: (1) History of malignant tumors; (2) had anti-tumor therapy before surgery; (3) Cannot cooperate with research plans; (4) pregnant or ready to conceive; (5) Participated in cancer drug clinical trials within four weeks; (6) The quantity or quality of the blood sample is insufficient; (7) Other reasons investigators believe that it is not suitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Circulating tumor DNA;—

Countries

China

Contacts

Public ContactChuanbo Xu
chuanbo_xu@hotmail.com+86 13827407694

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026